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Sickle cell disease (SCD) is a heritable disorder due to a missense point mutation in hemoglobin  β chain, due to the 
replacement of glutamic acid by valine in the sixth codon of the globin gene. This mutation is responsible for the 
production of abnormal-shaped red blood cells (RBCs) during stress conditions. RBCs bearing the mutated globin are 
vulnerable to intravascular hemolysis, highly adhesives and can easily interact with other blood cells, promoting 
inflammation and vaso-occlusion, which factors contribute to organs damages and impaired organs function. The 
transcription factor Nuclear factor–erythroid 2-related factor 2 (Nrf2) mediates adaptation to oxidative stress and cell 
defense. Under homeostatic conditions, Nrf2 is sequestered by Keap1 (Kelch-like ECH-associated protein 1) in the 
cytosol and degraded through the proteasomal pathway. Upon exposure to stress stimuli, such as ROS or electrophiles, 
Nrf2 is stabilized and translocate into the nucleus where it activates transcription of cytoprotective and antioxidants 
genes. 
 
I here elucidate the benefit of genetic induction of Nrf2 through the ablation of its cytosolic repressor Keap1, using a 
SCD knock-in mouse model bearing human mutated globin loci, crossed with mutated Keap1, I generate a compound 
mutant (hβS/S::Keap1F/–) mice, in which Nrf2 was constitutively activated. To confirm the activation of Nrf2, I measured 
Nrf2 protein level by western blot and as expected , there was slightly increase of Nrf2 protein expression in liver and 
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lungs of hβS/S::Keap1+/+ mice when compared to control hβA/S::Keap1+/+ mice while significant increase protein level of 
Nrf2 was observed in hβS/S::Keap1F/– mice.  It reported that sickle cell patients bear higher leucocytes count than non 
sickle patients. The hβS/S::Keap1+/+  mice showed higher leucocytes count than control mice, and interestingly  I 
observed markedly reduced the number of leucocytes in Nrf2 activated mice (hβS/S::Keap1F/– mice). Histological analysis 
of the liver and lungs revealed that congestion and necrosis regions observed in SCD (hβS/S::Keap1+/+)  mice, were 
significantly lessened in hβS/S::Keap1F/–. Moreover, liver damage marker alanine transferase (ALT) plasma level was 
decreased in hβS/S::Keap1F/– when compared to hβS/S::Keap1+/+ mice. I further examined inflammatory status using 
human IL6 reporter mice system and found that luciferase activity reflecting expression of human IL6 gene was 
markedly seen in SCD mice than control mice, while Nrf2 activation in SCD significantly lowered that activity. More 
interestingly, mRNA expression levels of IL-6, IL-1 β and IL-18 measured by PCR in lung homogenates of all mice, 
revealed that these pro inflammatory cytokines were highly expressed in hβS/S::Keap1+/+ mice than in hβA/S::Keap1+/+ 
control mice, and markedly repressed with Nrf2 activation. In addition measured adhesion molecules expression in aorta 
by PCR shows their important repression in hβS/S::Keap1F/- mice. Although Nrf2 activation did not substantially modify 
stress erythropoiesis as well as hemolysis in hβS/S::Keap1F/- mice, plasma heme and heme metabolites (Total and indirect 
biluribin) levels were significantly decreased when compared with hβS/S::Keap1+/+ mice. These results demonstrate that 
Nrf2 activation in SCD does not only repress pro-inflammatory cytokines and adhesion molecules, but also preserves 
organs from heme and oxidative stress mediated injuries, independently from improvement of hemolysis 
 
To determine whether pharmacological compounds that induce Nrf2 could procure same effects as genetic activation of 
Nrf2, CDDO-Im (2-cyano-3, 12 dioxooleana-1, 9 diene-28-imidazolide) was given to h βS/S mice for three weeks. After 
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treatment, I observe gradually decreasing numbers of WBC (white blood cells) in hβS/S CDDO-Im treated mice 
compared h βS/S vehicle treated mice. Also PCR analysis of mRNA expression of pro-inflammatory cytokines revealed 
significant decrease of IL-6 and IL-1 β in the lungs of CDDO-Im-treated hβS/S mice. Furthermore liver section of hβS/S 
CDDO-Im treated mice showed impressive amelioration of necrotic lesions. These results indicate that administration of 
a chemical Nrf2 inducer relieves inflammation and organ damage in hβS/S mice. Collectively, these data provide the 
evidence that Nrf2 activation improves ROS-mediated organ damages and inflammation. Since endogenous Nrf2 protein 
is likely to be insufficient to overcome the abiding oxidative stress in SCD shown by the slight increase of Nrf2 protein 
level, I believe that further boost up of Nrf2 with pharmacological molecules will be beneficial for synergic therapy in 
medical care of sickle patients. 
	  
